| Source: | A semisynthetic derivate of Geldanamycin |
| Synonyms | 17-(Allylamino)-17-demethoxy- geldanamycin, 17AAG |
| Description: | 17AAG is an ansamycin antibiotic which binds to Hsp90 (Heat Shock Protein 90) and alters it function. 17AAG is less hepatotoxic than Geldanamycin
|
| CAS number: | 75747-14-7 |
| Merck index: | |
| Molecular weight: | 585.7 |
| Structure: | 
 |
| Molecular Formula: | C31H43N3O8 |
Solubility
information | DMSO, Methanol. |
| Specifications |
|
| Appearance: | Purple powder |
| Purity | At least 98% by TLC, HPLC |
λmax: | |
| Melting point |
207°C
- 208°C |
| Solubility | Clear purple solution at 10mg/ml of Methanol |
| Storage | -20°C. Protect from light. |
| Applications | Same as Geldanamycin. 17-AAG is less hepato-toxic than Geldanamycin |
| Warnings | |
| Classification | benzoquinone ansamycin antibiotic
geldanamycin derivate
HSP90 inhibitor |
| Related products |
Geldanamycin, 17DMAG
|
| | For Research use only. Not for Human or Drug use
GMP/API grade available on request
17AAG by Fermentek is not produced from or contains any ingredients from animal origin.
No genetically modified organisms are used. |
| Publications | |
| | Barresi V, Fortuna CG, Garozzo R, Musumarra G, Scire S, Condorelli DF.
Identification of genes involved in the sensitivity to antitumour drug 17-allylamino,17-demethoxygeldanamycin (17AAG).
Mol Biosyst. 2006 May;2(5):231-9 |
| | Georgakis GV, Younes A.
Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Future Oncol. 2005 Apr;1(2):273-81. Review. |
| | Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ.
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Clin Cancer Res. 2005 May 1;11(9):3385-91 |
| | Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Cancer Chemother Pharmacol. 2005 Aug;56(2):126-37 |
| | Chen X, Bies RR, Ramanathan RK, Zuhowski EG, Trump DL, Egorin MJ.
Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
Cancer Chemother Pharmacol. 2005 Mar;55(3):237-43. Epub 2004 Oct 19 |
| | Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM.
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon cancer models.
J Natl Cancer Inst. 2003 Nov 5;95(21):1624-33. |
| | Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L.
17AAG: low target binding affinity and potent cell activity--finding an explanation.
Mol Cancer Ther. 2003 Feb;2(2):123-9. |
| | 17aag, 17dmag, Geldanamycin review |
|
|
